66 results on '"Chang, Joe Y."'
Search Results
2. American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy
3. Appropriate Use Criteria (AUC) for the Management of Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Guidelines from the American Radium Society
4. Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept
5. SwarmDeepSurv: swarm intelligence advances deep survival network for prognostic radiomics signatures in four solid cancers
6. How 3 Academic Centers Prescribe Stereotactic Body Radiation Therapy for Primary Lung Cancer
7. Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non–small-cell Lung Cancer
8. Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease
9. Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields
10. Consensus Statement on Proton Therapy in Mesothelioma
11. Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC
12. American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020
13. American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC
14. Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC
15. Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies
16. Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies
17. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer
18. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC
19. Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC
20. Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC
21. Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non–small-cell Lung Cancer
22. Accounting for, Mitigating, and Choice of Margins for Moving Tumors
23. Implications for high-precision dose radiation therapy planning or limited surgical resection after percutaneous computed tomography-guided lung nodule biopsy using a tract sealant
24. Reirradiation of thoracic cancers with intensity modulated proton therapy
25. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial
26. Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity
27. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Nodal Staging of Stereotactic Ablative Body Radiotherapy Patients
28. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial
29. Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions
30. Prospective Study of Patient-Reported Symptom Burden in Patients With Non–Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy
31. Incidence and predictors of severe acute esophagitis and subsequent esophageal stricture in patients treated with accelerated hyperfractionated chemoradiation for limited-stage small cell lung cancer
32. Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer: What We Have Learned
33. Intensity-Modulated Radiotherapy, Not 3 Dimensional Conformal, Is the Preferred Technique for Treating Locally Advanced Lung Cancer
34. Use of Simultaneous Radiation Boost Achieves High Control Rates in Patients With Non–Small-Cell Lung Cancer Who Are Not Candidates for Surgery or Conventional Chemoradiation
35. In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation
36. Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting
37. Prospective Exploratory Analysis of Cardiac Biomarkers and Electrocardiogram Abnormalities in Patients Receiving Thoracic Radiation Therapy with High-Dose Heart Exposure
38. Re-evaluating the Optimal Radiation Dose for Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
39. Chapter 9 - Pleural Tumors
40. Therapy-Resistant Cancer Stem Cells Have Differing Sensitivity to Photon versus Proton Beam Radiation
41. Can Stereotactic Ablative Radiotherapy in Early Stage Lung Cancers Produce Comparable Success as Surgery?
42. Clinical Controversies: Proton Therapy for Thoracic Tumors
43. Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer
44. The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy
45. Improving cardiac dosimetry: Alternative beam arrangements for intensity modulated radiation therapy planning in patients with carcinoma of the distal esophagus
46. Improving Radiation Conformality in the Treatment of Non–Small-Cell Lung Cancer
47. Pathologic T0N1 Esophageal Cancer After Neoadjuvant Therapy and Surgery: An Orphan Status
48. Outcomes with Esophageal Cancer Radiation Therapy
49. Patterns of Cardiac Perfusion Abnormalities After Chemoradiotherapy in Patients with Lung Cancer
50. CHAPTER 18 - Lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.